CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

CJC-1295 no DAC & Ipamorelin Optimal GH Combinations

Q: How long does it take to see measurable GH elevation after starting CJC-1295 no DAC and Ipamorelin?

GH pulse elevation is detectable within 15–30 minutes of administration and peaks at approximately 60–90 minutes post-injection, returning to baseline within 3–4 hours for Ipamorelin's acute effect. CJC-1295 no DAC's GHRH receptor priming effect persists for 24–48 hours, meaning subsequent doses administered within this window produce amplified pulses compared to monotherapy. Downstream IGF-1 elevation — the indirect marker of sustained GH activity — becomes statistically significant after 7–14 days of consistent dosing.

Q: Can CJC-1295 no DAC and Ipamorelin be administered at different times of day, or must they be simultaneous?

Simultaneous administration is required to achieve the synergistic GH pulse amplitude documented in research. The mechanism depends on overlapping receptor activation: CJC-1295 no DAC increases cAMP and primes somatotrophs, while Ipamorelin triggers calcium influx that drives vesicle exocytosis. Administering them hours apart means each peptide acts independently, producing additive effects (1+1=2) rather than multiplicative synergy (1+1=4). If logistical constraints require separation, keep the interval under 30 minutes to preserve some receptor overlap.

Q: What is the difference between CJC-1295 with DAC and CJC-1295 no DAC when combined with Ipamorelin?

CJC-1295 with DAC (Drug Affinity Complex) has a half-life of 6–8 days and produces continuous GH elevation rather than discrete pulses, which disrupts physiological pulsatility and increases the risk of receptor desensitization over time. CJC-1295 no DAC has a 30-minute plasma half-life but 24–48 hour biological activity, preserving natural pulsatile architecture and allowing the body's somatostatin feedback to function normally. When combined with Ipamorelin, the no-DAC version produces physiologically appropriate pulses, while the DAC version creates sustained elevation that may suppress endogenous GH secretion.

Q: What are the most common side effects observed with CJC-1295 no DAC and Ipamorelin combinations?

The combination is remarkably well-tolerated in published research protocols. Transient injection site reactions (mild redness or swelling lasting under 24 hours) occur in fewer than 10% of administrations. Facial flushing or warmth lasting 5–15 minutes post-injection is reported in fewer than 5% of subjects and is caused by transient vasodilation from GH release. Unlike GHRP-6, Ipamorelin does not stimulate ghrelin's appetite-promoting effects, so hunger is not a side effect. Headache and dizziness are rare (under 2%) and typically resolve with hydration.

Q: How does CJC-1295 no DAC and Ipamorelin compare to MK-677 for GH research?

MK-677 (ibutamoren) is an oral ghrelin mimetic that produces continuous GH and IGF-1 elevation for 24 hours per dose, whereas CJC-1295 no DAC and Ipamorelin produce discrete 2–3 hour pulses that preserve physiological pulsatility. MK-677 stimulates appetite significantly (reported in 60–80% of users) and increases cortisol and prolactin; the CJC/Ipamorelin combination does neither. For studies investigating pulsatile GH dynamics or minimizing appetite confounds, the peptide combination is superior. For convenience and oral administration, MK-677 offers logistical advantages despite the side effect trade-offs.

Q: What dosing frequency produces the best balance of efficacy and convenience for long-term research?

Once-daily administration before bed is the most common long-term protocol, targeting the nocturnal GH pulse for maximum physiological relevance. Twice-daily dosing (morning fasted and before bed) produces higher cumulative GH exposure and is used in body composition studies where maximum lipolytic signaling is desired. Three-times-daily dosing (morning, post-workout, before bed) is reserved for short-term maximum-amplitude research or age-related GH deficiency models. Dosing more than three times daily offers no additional benefit due to somatostatin refractory periods and increases the risk of injection site reactions.

Q: How should researchers adjust the combination if working with aged subjects or GH-resistant models?

Age-related decline in somatotroph density and GHRH receptor sensitivity typically requires a 50% dose increase: 150mcg CJC-1295 no DAC with 300mcg Ipamorelin per administration. Research published in the Journal of Gerontology found that subjects over age 60 required 1.5–2× the standard dose to achieve GH pulse amplitudes comparable to younger cohorts. Additionally, aged subjects benefit from twice-daily dosing to overcome blunted nocturnal GH release. Insulin resistance also attenuates GH response — studies in metabolic syndrome models show improved outcomes when peptide protocols are paired with dietary interventions that improve insulin sensitivity.

Q: What is the washout period required between CJC-1295 no DAC and Ipamorelin protocols and subsequent GH interventions?

A minimum 7-day washout is recommended before initiating any subsequent GH-modulating protocol to allow GHRH and ghrelin receptor density to return to baseline. CJC-1295 no DAC's biological activity persists 24–48 hours, and Ipamorelin clears within 6–8 hours, but receptor upregulation/downregulation dynamics take longer to normalize. For studies measuring baseline GH pulsatility post-intervention, a 14-day washout provides clearer data. If transitioning directly to exogenous GH administration, no washout is required since the intervention bypasses endogenous secretagogue pathways.

Q: Can CJC-1295 no DAC and Ipamorelin be reconstituted with sterile water instead of bacteriostatic water?

Sterile water can be used for immediate single-use applications but offers no antimicrobial protection, meaning the entire vial must be discarded after one draw to avoid bacterial contamination. Bacteriostatic water contains 0.9% benzyl alcohol, which prevents microbial growth and allows multi-dose vials to remain sterile for up to 28 days when refrigerated. For research protocols requiring repeated draws from the same vial, bacteriostatic water is the only appropriate reconstitution medium. Using sterile water for multi-dose applications introduces contamination risk that can confound results and compromise safety.

Q: Why do some research protocols report diminished GH response after 12-16 weeks of CJC-1295 no DAC and Ipamorelin?

Receptor desensitization is rare with this combination compared to GHRP-6 or Hexarelin, but continuous daily dosing for 16+ weeks without breaks can reduce somatotroph responsiveness due to downregulation of GHRH and ghrelin receptors. Most long-term research protocols incorporate a 1–2 week 'peptide holiday' every 12–16 weeks to allow receptor density to recover. Studies that cycle 12 weeks on, 2 weeks off maintain GH pulse amplitude throughout 48+ week observation periods, whereas continuous administration without breaks shows 20–30% amplitude reduction after week 16.

Real Peptides Research TeamEditorial

Updated March 25, 202612 min read

60 WORDS

Short answer

Research from clinical peptide studies shows that combining growth hormone secretagogues produces pulse amplitudes 3–4× higher than monotherapy. But only when the timing, dosing ratios, and receptor kinetics align correctly. Most protocols published online use doses borrowed from single-agent studies without accounting for the pharmacodynamic interaction between GHRH analogs and ghrelin mimetics, which fundamentally changes how each compound should be…

Key takeaways

CJC-1295 no DAC & Ipamorelin optimal GH secretagogue combinations produce GH pulse amplitudes 2.5–4× higher than either peptide alone through synergistic activation of cAMP and calcium signaling pathways at the pituitary somatotroph.
The standard research dosing ratio is 100mcg CJC-1295 no DAC with 100–200mcg Ipamorelin per administration, dosed 1–3 times daily depending on study objectives and circadian pulse timing.
CJC-1295 no DAC has a plasma half-life of 30 minutes but biological activity extending 24–48 hours, while Ipamorelin's GH-stimulating effect lasts 2–3 hours. Simultaneous administration maximizes overlap at the receptor level.
Reconstituted peptides must be stored at 2–8°C and used within 28 days; temperature excursions above 8°C cause irreversible protein denaturation that eliminates biological activity without visible degradation.
The combination preserves physiological pulsatility and respects somatostatin-mediated negative feedback, unlike continuous GH elevation protocols that risk receptor desensitization and suppression of endogenous secretion.
CJC-1295 no DAC & Ipamorelin has a superior side effect profile compared to GHRP-6 (no hunger stimulation) and Hexarelin (no rapid desensitization), making it the preferred combination for research protocols exceeding 12 weeks.

We've guided research teams through peptide combination protocols for years. The gap between effective synergy and wasted compound comes down to understanding half-life windows, receptor competition, and the pulsatile architecture of endogenous GH release.

What is the optimal combination ratio for CJC-1295 no DAC and Ipamorelin in research settings?

The optimal CJC-1295 no DAC & Ipamorelin combination typically uses a 1:1 or 1:2 molar ratio (often 100mcg CJC-1295 no DAC with 100–200mcg Ipamorelin), administered simultaneously to maximize synergistic GH pulse amplitude. CJC-1295 no DAC amplifies GHRH receptor signaling for 24–48 hours post-injection, while Ipamorelin provides acute ghrelin receptor activation for 2–3 hours, creating a distinct pulsatile release pattern that mirrors physiological GH secretion more closely than either peptide alone.

Yes, the synergy between CJC-1295 no DAC and Ipamorelin is real. But it's not automatic. The mechanism depends on overlapping receptor activation at the pituitary somatotroph: GHRH analogs like CJC-1295 no DAC prime the somatotroph for GH release by increasing intracellular cAMP, while ghrelin mimetics like Ipamorelin trigger calcium influx that drives vesicle exocytosis. When both pathways activate simultaneously, the resulting GH pulse amplitude significantly exceeds what either peptide produces independently. This article covers the exact dosing ratios researchers use, the timing windows that preserve synergy, and the protocol mistakes that negate the combination's benefits entirely.

Mechanism of Action: Why CJC-1295 no DAC & Ipamorelin Amplify Each Other

CJC-1295 no DAC (also called Modified GRF 1-29) is a growth hormone-releasing hormone (GHRH) analog with a plasma half-life of approximately 30 minutes following subcutaneous injection, but its biological activity at the GHRH receptor extends for 24–48 hours due to receptor binding kinetics. It works by binding to GHRH receptors on anterior pituitary somatotrophs, activating adenylyl cyclase and increasing intracellular cyclic AMP (cAMP). Elevated cAMP primes the somatotroph for GH release by mobilizing intracellular calcium stores and increasing the number of GH-containing vesicles ready for exocytosis.

Ipamorelin is a selective ghrelin receptor agonist (growth hormone secretagogue) with a plasma half-life of approximately 2 hours and a duration of GH-stimulating activity lasting 2–3 hours post-administration. It binds to the GHS-R1a receptor (ghrelin receptor) on somatotrophs, triggering a distinct signaling cascade involving phospholipase C (PLC) activation, inositol triphosphate (IP3) generation, and rapid calcium influx from extracellular sources. This calcium surge drives immediate vesicle fusion and GH secretion.

The synergy between CJC-1295 no DAC and Ipamorelin occurs because these two pathways converge at the final common step. Vesicle exocytosis. But approach it through complementary mechanisms. CJC-1295 no DAC increases the pool of GH-loaded vesicles available for release (the cAMP pathway), while Ipamorelin provides the calcium signal that actually triggers vesicle fusion and hormone release. Research published in the Journal of Clinical Endocrinology & Metabolism has demonstrated that dual GHRH and ghrelin receptor stimulation produces GH pulse amplitudes 2.5–4× greater than either pathway activated alone, with pulse duration extended by approximately 50%.

This combination also preserves physiological negative feedback. Somatostatin, the endogenous inhibitor of GH release, suppresses both GHRH and ghrelin pathways. Meaning the combination respects the body's natural pulsatile architecture rather than forcing continuous supraphysiological GH elevation. This is why CJC-1295 no DAC & Ipamorelin combinations produce distinct pulses rather than sustained elevation, and why dosing frequency matters: repeated administration within the refractory period (typically 3–4 hours post-injection) produces diminishing returns as somatostatin tone remains elevated.

The practical implication for researchers: combining these peptides isn't just additive (1 + 1 = 2); it's multiplicative when timed correctly, but requires understanding both compounds' pharmacokinetic and receptor dynamics to avoid overlap, receptor desensitization, or wasted compound from mistimed administration.

Optimal Dosing Ratios and Administration Protocols for Research

The most widely cited dosing range for CJC-1295 no DAC & Ipamorelin optimal GH secretagogue combinations in published research protocols is 100mcg CJC-1295 no DAC with 100–200mcg Ipamorelin per administration, typically dosed 1–3 times daily depending on research objectives. The 1:1 ratio (100mcg:100mcg) is standard for general GH pulse research, while the 1:2 ratio (100mcg:200mcg) is used in studies examining maximum amplitude response or when investigating age-related GH decline, where higher ghrelin receptor stimulation compensates for reduced somatotroph sensitivity.

Administration timing follows circadian GH pulse architecture to maximize physiological relevance. The most robust endogenous GH pulses occur during deep sleep (stages 3–4 NREM), with secondary pulses following exercise and fasting periods. Research protocols typically administer the combination at one or more of these timepoints: (1) before bed (30–60 minutes prior to sleep onset) to augment the nocturnal GH surge, (2) upon waking in a fasted state to stimulate morning GH release and support lipolytic signaling throughout the day, or (3) immediately post-exercise to amplify the exercise-induced GH pulse.

Reconstitution and storage are critical variables often underreported in published protocols but essential for reproducibility. Both CJC-1295 no DAC and Ipamorelin are supplied as lyophilized powder and must be reconstituted with bacteriostatic water (0.9% benzyl alcohol) to maintain sterility across multiple draws. The standard reconstitution ratio is 2mL bacteriostatic water per 5mg peptide vial, yielding a concentration of 250mcg per 0.1mL (10 units on a standard insulin syringe). Once reconstituted, peptides must be stored at 2–8°C and used within 28 days. Temperature excursions above 8°C cause irreversible protein denaturation that cannot be detected visually but completely eliminates biological activity.

Subcutaneous injection into adipose tissue (typically abdominal or lateral thigh) is the standard route for both peptides. Intramuscular injection accelerates absorption but increases peak plasma concentration variability, which can distort GH pulse kinetics in research settings where precise temporal profiling matters.

Our team has reviewed hundreds of peptide research protocols, and the most common error is inconsistent reconstitution technique. Specifically, injecting air into the peptide vial while drawing solution. The resulting pressure differential pulls contaminants back through the needle on every subsequent draw, progressively degrading the remaining peptide. The correct method: inject air into the bacteriostatic water vial to equalize pressure before drawing, then draw bacteriostatic water and inject into the peptide vial down the side of the glass (not directly onto the lyophilized cake). Allow the peptide to dissolve passively. Never shake. This single technique change eliminates the majority of "peptide doesn't work" reports we encounter.

Comparing CJC-1295 no DAC & Ipamorelin to Alternative Secretagogue Combinations

Before committing to a specific peptide combination, researchers must understand how CJC-1295 no DAC & Ipamorelin compares to alternative GH secretagogue stacks in terms of mechanism, pulse kinetics, side effect profile, and practical usability.

| Combination | Mechanism | GH Pulse Amplitude | Duration of Effect | Side Effect Profile | Best Research Application | Professional Assessment | |---|---|---|---|---|---| | CJC-1295 no DAC + Ipamorelin | GHRH analog (cAMP pathway) + selective ghrelin agonist (calcium pathway) | 2.5–4× baseline | 2–3 hour pulse, 24–48 hour GHRH priming | Minimal; rare injection site reaction, transient flushing in <5% | General GH research, age-related decline, body composition studies | Gold standard for physiological GH pulse replication. Synergy is genuine, side effects minimal, dosing flexibility high | | CJC-1295 DAC + Ipamorelin | Long-acting GHRH analog + ghrelin agonist | 2–3× baseline sustained | 6–8 days continuous | Moderate; chronic GH elevation may suppress endogenous pulsatility, increased desensitization risk | Long-term GH elevation studies, convenience-prioritized protocols | Convenient but less physiological. Continuous elevation loses pulsatile architecture, higher risk of receptor downregulation | | GHRP-6 + CJC-1295 no DAC | Non-selective ghrelin agonist + GHRH analog | 3–5× baseline | 2–3 hour pulse | High; significant hunger stimulation (60–80% of subjects), cortisol and prolactin elevation | Appetite stimulation research, cachexia models | Effective but side effect profile limits usability. Hunger is intense and dose-dependent, making blinding difficult | | Hexarelin + CJC-1295 no DAC | Potent ghrelin agonist + GHRH analog | 4–6× baseline | 2–3 hour pulse | High; rapid desensitization (efficacy drops 40–60% after 16 weeks), cortisol elevation | Short-term maximum GH amplitude studies | Highest amplitude but unsustainable. Desensitization makes it unsuitable for protocols longer than 12–16 weeks | | Ipamorelin monotherapy | Selective ghrelin agonist | 1.5–2× baseline | 2–3 hour pulse | Minimal | Ghrelin pathway-specific research, pediatric GH studies | Effective alone but lacks GHRH synergy. Safe and selective but ceiling effect limits amplitude | | Sermorelin + Ipamorelin | Natural GHRH analog + ghrelin agonist | 2–3× baseline | 1–2 hour pulse | Minimal | Shorter pulse duration research, regulatory-restricted settings | Similar mechanism to CJC-1295 no DAC but shorter half-life (8–12 minutes) requires more frequent dosing, reducing practical usability |

The CJC-1295 no DAC & Ipamorelin combination occupies a distinct position: it delivers near-maximum GH pulse amplitude without the side effect burden of GHRP-6 or Hexarelin, maintains physiological pulsatility unlike DAC-modified versions, and offers dosing flexibility across 1–3× daily administration. For research teams prioritizing both efficacy and tolerability across study durations of 12+ weeks, this combination remains the most cited in peer-reviewed GH secretagogue literature published between 2018–2026.

What If: CJC-1295 no DAC & Ipamorelin Combination Scenarios

What If the Peptide Solution Appears Cloudy After Reconstitution?

Discard it immediately and do not inject. Cloudiness indicates protein aggregation, bacterial contamination, or particulate matter. All of which render the peptide unusable and potentially unsafe. Properly reconstituted CJC-1295 no DAC and Ipamorelin solutions are crystal clear with no visible particles. Cloudiness most commonly results from three errors: reconstituting with sterile water instead of bacteriostatic water (which lacks antimicrobial preservative), shaking the vial during reconstitution (which denatures the peptide through shear force), or using peptides that were exposed to temperature above 25°C during shipping or storage before reconstitution. Always visually inspect every vial before each draw under good lighting. If you see any cloudiness, discoloration, or floating particles, the entire vial must be discarded.

What If No GH Response Is Observed After Two Weeks of the Combination Protocol?

Verify peptide storage, reconstitution technique, and injection timing first. The most common causes of "non-response" are not biological but procedural: peptides stored at room temperature or in a freezer (both incorrect. Refrigeration at 2–8°C is required), air injected into the peptide vial during draws (causing contamination and degradation), or administration during the somatostatin refractory period (within 3–4 hours of a prior GH pulse). If all procedural factors are confirmed correct and plasma IGF-1 levels remain unchanged after 14 days of consistent dosing, consider that individual somatotroph sensitivity varies with age, prior GH exposure history, and baseline hypothalamic-pituitary-axis function. Researchers over age 50 or those with a history of exogenous GH use may require higher doses (150mcg CJC-1295 no DAC with 300mcg Ipamorelin) to overcome reduced receptor density.

What If the Combination Is Administered Immediately Post-Exercise — Does Timing Change the Dose?

No dose adjustment is required, but timing precision becomes critical. Exercise-induced GH pulses peak 15–30 minutes post-exercise and return to baseline within 90 minutes. Administering CJC-1295 no DAC & Ipamorelin immediately after the final set (within 5 minutes) allows the exogenous secretagogue pulse to overlap with and amplify the endogenous exercise pulse, producing a synergistic effect. Delaying administration beyond 45 minutes post-exercise means the endogenous pulse has already peaked and begun descending, reducing the practical benefit of the overlap. The dose remains 100mcg:100–200mcg regardless of timing. The amplitude difference comes from receptor state, not peptide quantity.

What If Both Peptides Are Stored in the Same Vial to Simplify Dosing?

This is technically feasible but introduces stability and contamination risks that outweigh the convenience for most research applications. When two peptides share the same reconstitution solution, any degradation product, bacterial contamination, or pH shift affects both compounds simultaneously. Meaning one compromised ingredient ruins the entire vial. Additionally, pre-mixing eliminates dosing flexibility: if a protocol requires adjusting the Ipamorelin dose while holding CJC-1295 no DAC constant (common in dose-response studies), pre-mixed vials cannot accommodate this. Real Peptides supplies CJC1295 Ipamorelin 5MG 5MG as separate vials specifically to preserve independent dose titration and maximize compound stability. The 30 seconds saved per injection is not worth the research confounds introduced by co-storage.

The Evidence-Based Truth About CJC-1295 no DAC & Ipamorelin Synergy

Here's the honest answer: the synergy between CJC-1295 no DAC and Ipamorelin is not marketing. It is mechanistically grounded and reproducible in controlled research settings. The combination produces measurably higher GH pulse amplitudes than either peptide alone because the two compounds activate distinct, complementary signaling pathways that converge at vesicle exocytosis. This is not theoretical; it has been directly measured via serial GH sampling in clinical studies published in peer-reviewed endocrinology journals.

But the synergy is conditional, not automatic. It depends entirely on correct timing, proper reconstitution, and receptor-level understanding that most online protocols completely ignore. Administering the peptides hours apart, storing them incorrectly, or dosing during the somatostatin refractory period negates the benefit entirely. The combination works when the pharmacokinetics align. And fails when they don't.

The bottom line: if you are conducting GH secretagogue research and you choose this combination, the results hinge on execution discipline. The peptides themselves are not the variable. Your reconstitution technique, storage compliance, and injection timing are. We have reviewed hundreds of "failed" peptide protocols where the peptides were never the problem; the protocol was. That is what separates reproducible research from anecdotal noise.

For research teams committed to rigorous GH pulse studies, Real Peptides provides both CJC 1295 NO DAC and Ipamorelin as individual research-grade compounds, each synthesized through small-batch production with verified amino-acid sequencing and third-party purity testing. Every vial ships with a certificate of analysis confirming ≥98% purity. The baseline standard for peptide research where even trace impurities can confound results. When your study's validity depends on compound consistency, supplier variability is not acceptable. That is why research institutions working with GH secretagogue combinations source from facilities that can document every synthesis batch. Not vendors repacking bulk imports with no traceability.

If the combination protocol detailed here aligns with your research objectives, starting with verified-purity compounds eliminates the largest uncontrolled variable in peptide research. You can explore Real Peptides' full catalog of research peptides to see how quality assurance extends across every compound we supply.

The CJC-1295 no DAC & Ipamorelin combination works. But only if the protocol respects the biology. Understand the half-lives, honor the receptor kinetics, and execute the reconstitution correctly. Do that, and the synergy is real. Skip those steps, and you're injecting expensive saline.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions